2026-23413NoticeWallet

FDA Eyes Flolipid Approval After Company Misses Annual Reports

Published Date: 11/18/2026

Notice

Summary

The FDA plans to pull the approval for Salerno Pharmaceuticals' Flolipid Suspension because the company hasn’t submitted required yearly reports. Salerno has until December 18, 2026, to ask for a hearing to explain themselves. This affects anyone using or selling Flolipid and could change its availability soon.

Analyzed Economic Effects

2 provisions identified: 1 benefits, 1 costs, 0 mixed.

FDA proposes to withdraw Flolipid approval

The FDA is proposing to withdraw approval of NDA 206679 for Flolipid suspension (20 mg/5 mL and 40 mg/5 mL) because Salerno Pharmaceuticals repeatedly failed to file required annual reports under 21 CFR 314.81. If approval is withdrawn, the Flolipid products covered by this NDA may not be lawfully introduced into interstate commerce.

Opportunity to seek hearing and submit evidence

Salerno Pharmaceuticals may request a hearing on the proposed withdrawal by December 18, 2026, and must submit all supporting data and analyses by January 19, 2027. Other interested persons may submit electronic or written comments by January 19, 2027; confidential submissions have special paper-submission procedures.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Comments Due
11/18/2026
1/19/2027

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register